Skip to main content
Premium Trial:

Request an Annual Quote

MDx Health Raises $11.7M

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – MDx Health today announced it has raised €8.2 million ($11.7 million) in gross proceeds from a private placement of new shares with investors.

Net proceeds from the financing round, which exceeds the company's target of at least €6 million announced on Monday, will go toward accelerating the development of new products in line with its business restructuring to concentrate on the molecular diagnostics space. MDx Health also will use the funds to set up a CLIA laboratory and hire a sales and marketing firm in the US.

Pursuant to the private placement, the Liege, Belgium-based firm will issue approximately 5.4 million new ordinary shares at an offer price of €1.50 per share, it said.

"In combination with our existing cash position, these funds allow us to accelerate the executive of our new business strategy and establish a US presence in the short term," Jan Groen, CEO of MDx Health, said in a statement.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.